Volume 12, Issue 6 (8-2014)                   IJRM 2014, 12(6): 377-0 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Eftekhar M, Pourmasumi S, Karimi-Zarchi M. Preservation of ovarian function during chemotherapy and radiotherapy in young women with malignancies. IJRM 2014; 12 (6) :377-0
URL: http://ijrm.ir/article-1-555-en.html
Preservation of ovarian function during chemotherapy and radiotherapy in young women with malignancies
Maryam Eftekhar1 , Soheila Pourmasumi1 , Mojgan Karimi-Zarchi * 2
1- Recearch and Clinical Center for Infertility, Shahid Sadughi University of Medical Sciences, Yazd, Iran
2- Department of Obstetrics and Gynecology, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran , drkarimi2001@yahoo.com
Abstract:   (2589 Views)
Malignancies are not rare in girl and women during their reproductive years. Over the past three decades, the survival rate for cancer has been improving due to progress in cancer diagnosis and treatment. These patients frequently experience a variety of treatment, and disease-related side effects that diminish their quality of life during and after treatment; among these are loss of fertility and sexual dysfunction. There have been recent advances in the field of fertility preservation, which can allow many of these genital cancer survivors to have children in the future. This topic review discusses available options and specific strategies for fertility preservation in adolescent and young women with malignancies who wish to preserve their ability to become pregnant in the future.
Keywords: Malignancy, Fertility preservation, Leukemia, Cervical cancer, Endometrial cancer, Ovarian cancer.
Full-Text [PDF 135 kb]   (505 Downloads) |   |   Full-Text (HTML)  (324 Views)  
Type of Study: Original Article |
References
1. Wallace W, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005; 6: 209. [DOI:10.1016/S1470-2045(05)70092-9]
2. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917-2931. [DOI:10.1200/JCO.2006.06.5888]
3. Loscalzo MJ, Clark KL. The psychosocial context of cancer-related infertility. Cancer Treat Res 2007; 138: 180-190. [DOI:10.1007/978-0-387-72293-1_13]
4. Colombo N, Parma G, Lapresa M, Maggi F, Piantanida P, Maggioni A. Role of conservative surgery in ovarian cancer: the European experience. Int J Gynecol Cancer 2005; 15: 206-211. [DOI:10.1111/j.1525-1438.2005.00428.x]
5. Maneo A, Chiari S, Bonazzi C, Mangioni C. Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer. Gynecol Oncol 2008; 111: 438-443. [DOI:10.1016/j.ygyno.2008.08.023]
6. Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 2003; 101: 251-257. [DOI:10.1097/00006250-200302000-00010]
7. Makar AP, Tropé C. Fertility preservation in gynecologic cancer. Acta Obstet Gynecol Scan 2001; 80: 794-802. [DOI:10.1034/j.1600-0412.2001.080009794.x]
8. Rodriguez-Wallberg KA, Oktay K. Options on fertility preservation in female cancer patients. Cancer Treatment Rev 2012; 38: 354-361. [DOI:10.1016/j.ctrv.2011.10.002]
9. Karimi-Zarchi M, Forat-Yazdi M, Vafaeenasab MR, Nakhaie-Moghadam M, Miratashi-Yazdi A, Teimoori S, et al. Evaluation of the effect of GnRH agonist on menstrual reversein breast cancer cases treated with cyclophosphamide. Eur J Gynaecol Oncol 2014; 35: 59-61.
10. Dursun P, LeBlanc E, Nogueira MC. Radical vaginal trachelectomy (Dargent's operation): a critical review of the literature. Eur J Surg Oncol 2007; 33: 933-941. [DOI:10.1016/j.ejso.2006.11.021]
11. Burnett AF, Roman LD, O'Meara AT, Morrow CP. Radical vaginal trachelectomy and pelvic lymphadenectomy for preservation of fertility in early cervical carcinoma. Gynecol Oncol 2003; 88: 419-423. [DOI:10.1016/S0090-8258(02)00142-7]
12. Zarchi MK, Mousavi A, Gilani MM, Barooti E, Rad OA, Ghaemmaghami F, et al. Fertility Sparing Treatments in Young Patients with Gynecological Cancers: Iranian Experience and Literature. Asian Pac J Cancer Prev 2011; 12: 1887-1892
13. Mathevet P, Laszlo dKE, Dargent D. [Fertility preservation in early cervical cancer]. Gynecol Obstet Fertil 2003; 31: 706-712. (In French) [DOI:10.1016/S1297-9589(03)00200-5]
14. Plante M, Renaud M-C, Hoskins IA, Roy M. Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol Oncol 2005; 98: 3-10. [DOI:10.1016/j.ygyno.2005.04.014]
15. Schlaerth JB, Spirtos NM, Schlaerth AC. Radical trachelectomy and pelvic lymphadenectomy with uterine preservation in the treatment of cervical cancer. Am J Obstet Gynecol 2003; 188: 29-34. [DOI:10.1067/mob.2003.124]
16. Plante M, Renaud M-C, François H, Roy M. Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature. Gynecol Oncol 2004; 94: 614-623. [DOI:10.1016/j.ygyno.2004.05.032]
17. Hertel H, Kohler C, Grund D, Hillemanns P, Possover M, Michels W, et al. Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer. Gynecol Oncol 2006; 103: 506-511. [DOI:10.1016/j.ygyno.2006.03.040]
18. Marie P, Harel F, Michel R. Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature. Gynecol Oncol 2004; 94: 614-623. [DOI:10.1016/j.ygyno.2004.05.032]
19. Weed Jr JC, Graff AT, Shoup B, Tawfik O. Small cell undifferentiated (neuroendocrine) carcinoma of the uterine cervix. J Am Coll Surg 2003; 197: 44-51. [DOI:10.1016/S1072-7515(03)00120-0]
20. Beth S, Stephanie J.L, Ann H.P, Carolyn D. R. Preserving Fertility After Cancer: A Cancer Journal for Clinicians2005; 55 : 211-228.
21. Covens A, Rosen B, Murphy J, Laframboise S, DePetrillo A, Lickrish G, et al. Changes in the demographics and perioperative care of stage IA(2)/ IB(1) cervical cancer over the past 16 years. Gynecol Oncol 2001; 81: 133-137. [DOI:10.1006/gyno.2001.6158]
22. Donnez J, Kim SS. Principles and practice of fertility preservation. Cambridge university press; New york.2011. [DOI:10.1017/CBO9780511921896]
23. Fagotti A, Gagliardi ML, Moruzzi C, Carone V, Scambia G, Fanfani F. Excisional cone as fertility-sparing treatment in early-stage cervical cancer. Fertil Steril 2011; 95: 1109-1112. [DOI:10.1016/j.fertnstert.2010.11.010]
24. Karimi-Zarchi M, Mousavi A, Gilani MM, Barooti E, Miratashi-Yazdi A, Dehghani A. Conservative treatment in early cervical cancer. Int J Biomed Sci 2013; 9: 123-128.
25. Karimi-Zarchi M, Mousavi A, Dehghani A. Conservative surgery in cervical cancer: report of two radical abdominal trachelectomies and literature review. Eur J Gynaecol Oncol 2011; 32: 710-712.
26. Plante M. Fertility preservation in the management of gynecologic cancers. Cur Opin Oncol 2000; 12: 497-507. [DOI:10.1097/00001622-200009000-00018]
27. Kimmig R, Strowitzki T, Moller-Höcker J, Kürzl R, Korell M, Hepp H. Conservative treatment of endometrial cancer permitting subsequent triplet pregnancy. Gynecol Oncol 1995; 58: 255-257. [DOI:10.1006/gyno.1995.1221]
28. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000; 7: 227-242. [DOI:10.1677/erc.0.0070227]
29. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update 2001; 7: 522-525. [DOI:10.1093/humupd/7.6.522]
30. Wang CB, Wang CJ, Huang HJ, Hsueh S, Chou HH, Soong YK, et al. Fertility‐preserving treatment in young patients with endometrial adenocarcinoma. Cancer 2002; 94: 2192-2198. [DOI:10.1002/cncr.10435]
31. Liou W-S, Yap OS, Chan JK, Westphal LM. Innovations in fertility preservation for patients with gynecologic cancers. Fertil Steril 2005; 84: 1561-1573. [DOI:10.1016/j.fertnstert.2005.03.087]
32. Rackow BW, Arici A. Endometrial cancer and fertility. Cur Opin Obstet Gynecol 2006; 18: 245. [DOI:10.1097/01.gco.0000193012.11523.c5]
33. Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012; 207: 1-12. [DOI:10.1016/j.ajog.2012.08.011]
34. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17: 1736-1744. [DOI:10.1200/JCO.1999.17.6.1736]
35. Karimi-Zarchi M, Mousavi AS, Behtash N, Chiti Z, Bokaie M. Conservative management of young women with endometrial carcinoma or complex atypical hyperplasia: report of three cases and literature review. Eur J Gynaecol Oncol 2011; 32: 695-698.
36. Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev 2010; 12: CD007926. [DOI:10.1002/14651858.CD007926.pub2]
37. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002; 186: 651-657. [DOI:10.1067/mob.2002.122130]
38. Rubin SC, Sutton GP. Ovarian cancer: Lippincott Williams & Wilkins; 2001.
39. Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer 2009; 115: 4118-4126. [DOI:10.1002/cncr.24461]
40. Duska LR, Chang Y, Flynn CE, Chen AH, Goodman A, Fuller AF, et al. Epithelial ovarian carcinoma in the reproductive age group. Cancer 1999; 85: 2623-2629. https://doi.org/10.1002/(SICI)1097-0142(19990615)85:12<2623::AID-CNCR19>3.0.CO;2-O [DOI:10.1002/(SICI)1097-0142(19990615)85:123.0.CO;2-O]
41. Winter III WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 3621-3627. [DOI:10.1200/JCO.2006.10.2517]
42. Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001; 82: 532-537. [DOI:10.1006/gyno.2001.6328]
43. Karimi Zarchi M, Mousavi A, Gilani MM, Barooti E, Amini Rad O, Ghaemmaghami F, et al. 57TFertility sparing treatments in young patients with gynecological cancers: Iranian experience and literature review.57T 59TAsian Pac J Cancer Prev59T 2011; 12: 1887-1892.
44. Thigpen T, Brady MF, Omura GA, Creasman WT, Mcguire WP, Hoskins WJ, et al. Age as a prognostic factor in ovarian carcinoma: The Gynecologic Oncology Group experience. Cancer 1993; 71: 606- 614. [DOI:10.1002/cncr.2820710218]
45. Seli E, Tangir J. Fertility preservation options for female patients with malignancies. Cur Opin Obstet Gynecol 2005; 17: 299-308. [DOI:10.1097/01.gco.0000169108.15623.34]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb